Upadacitinib, a drug used to treat atopic dermatitis (AD), may potentially induce alopecia areata, a case study suggests.

ZORYVE foam represents the first topical treatment for seborrheic dermatitis with a new mechanism of action approved in Canada in over two ...

Primary care physicians (PCPs) play a key role in treating young patients as they progress through the "atopic march" from ...

Later on in the day, confirmation finally came in – Zoryve had been approved as a new, once-daily treatment for mild to moderate atopic ... dermatitis that mainly affects the scalp.

Black people in the US are not only more likely than other folks to get eczema in childhood, but may have harder-to-treat or ...

May occur as a result of atopic and/or contact dermatitis. Arms, legs, back of the neck, backs of the hand, bottoms of the feet, scalp ... Eczema treatments that are scented or that contain ...

Q3 2024 Earnings Conference Call October 15, 2024 8:30 AM ETCompany ParticipantsJessica Moore - Vice President, ...

Good morning, and welcome to Johnson & Johnson's third-quarter 2024 earnings conference call. (Operator Instructions) This call is being recorded. If anyone has any objections, you may disconnect at ...

Results of a retrospective real-world study suggested no greater risk for major CV adverse events in patients treated with ...

Methods for diagnosing cases of canine atopic dermatitis were covered during a session at the 2024 Fetch Coastal dvm360 ...

Roflumilast cream 0.15% is a safe and efficacious treatment for mild to moderate atopic dermatitis among children, adolescents, and adults.

This article explores how seborrheic dermatitis impacts Black Americans and why the condition may manifest differently in ...